HC Wainwright Issues Pessimistic Estimate for ONCY Earnings

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Stock analysts at HC Wainwright cut their FY2024 earnings per share estimates for shares of Oncolytics Biotech in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.30) per share for the year, down from their previous estimate of ($0.29). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.06) EPS, FY2026 earnings at ($0.30) EPS, FY2027 earnings at ($0.29) EPS and FY2028 earnings at ($0.09) EPS.

ONCY has been the topic of a number of other reports. Leede Financial downgraded shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research report on Wednesday, November 13th. Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday.

Oncolytics Biotech Stock Down 3.0 %

Shares of ONCY opened at $0.98 on Monday. The stock’s fifty day simple moving average is $1.09 and its 200-day simple moving average is $1.05. The firm has a market capitalization of $75.53 million, a PE ratio of -3.63 and a beta of 1.69. Oncolytics Biotech has a 12-month low of $0.84 and a 12-month high of $1.75.

Institutional Investors Weigh In On Oncolytics Biotech

An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC acquired a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 0.07% of Oncolytics Biotech at the end of the most recent quarter. 6.82% of the stock is currently owned by institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.